

11-15-06

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

8 +
14 Refs.

Application Number

10/808,880

Filing Date

March 24, 2004

First Named Inventor

Steven M. WATKINS

Art Unit

1651

Examiner Name

S. Saucier

Attorney Docket Number

475512000400

ENCLOSURES (Check all that apply)☐ Fee Transmittal Form☐ Fee Attached☐ Amendment/Reply☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement
(Supplemental - 3 pages)☐ Certified Copy of Priority
Document(s)☐ Reply to Missing Parts/
Incomplete Application☐ Reply to Missing Parts under
37 CFR 1.52 or 1.53☐ Drawing(s)☐ Licensing-related Papers☐ Petition☐ Petition to Convert to a
Provisional Application☐ Power of Attorney, Revocation
Change of Correspondence Address☐ Terminal Disclaimer☐ Request for Refund☐ CD, Number of CD(s) _____☐ Landscape Table on CD☐ After Allowance Communication
to TC☐ Appeal Communication to Board of
Appeals and Interferences☐ Appeal Communication to TC
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Other Enclosure(s) (please
Identify below):

1. Form PTO/SB/08a/b + copy
(4 pages)
2. Fourteen (14) References
3. Return Receipt Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

MORRISON & FOERSTER LLP (Customer No. 25226)

Signature

Printed name

Alicia J. Hager

Date

November 13, 2006

Reg. No.


44,140

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 596703435 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: November 13, 2006

Signature: _____

(Lori Sims)



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Air Mail No. EV 596703435 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: November 13, 2006 Signature: _____

Lori Sims
(Lori Sims)

Patent
Docket No. 475512000400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Steven M. WATKINS

Serial No.: 10/808,880

Filing Date: March 24, 2004

For: METHODS OF USING QUANTITATIVE
LIPID METABOLOME DATA

Examiner: S. Saucier

Group Art Unit: 1651

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of ___ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other


Application Serial No. 10/808,880

Patent
Docket No. 475512000400


fees due in connection with the filing of this document to **Deposit Account No. 03-1952**
referencing 475512000400.

Dated: November 13, 2006

Respectfully submitted,

By 
Alicia J. Hager
Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08a/b (07-05)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/808,880
				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	1	of	2	Attorney Docket Number	475512000400

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2004/0024065-A1	02-05-2004	Watkins et al.	
	2.	US-2004/0143461-A1	07-22-2004	Watkins	
	3.	US-2006/0084129-A1	04-20-2006	Watkins	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	4.	Füchtenbusch, M. et al. (2000). "Clinical Efficacy of New Thiazolidinediones and Glitazones in the Treatment of Type 2 Diabetes Mellitus," <i>Exp. Clin. Endocrinol. Diabetes</i> 108:151-163.		
	5.	Holub, B.J. et al. (1987). "Nutritional Regulation of Cellular Phosphatidylinositol," Section 21 <i>In Methods in Enzymology</i> , Volume 141, Conn, P.M. et al. eds., Academic Press Inc.: Orlando, FL, pp. 234-244.		
	6.	Horton, J.D. et al. (May 2002). "SREBPs: Activators of the Complete Program of Cholesterol and Fatty Acid Synthesis in the Liver," <i>The Journal of Clinical Investigation</i> 109(9):1125-1131.		
	7.	Jump, D.B. et al. (1994). "Coordinate Regulation of Glycolytic and Lipogenic Gene Expression by Polyunsaturated Fatty Acids," <i>Journal of Lipid Research</i> 35:1076-1084.		
	8.	Kersten, S. et al. (June 1999). "Peroxisome Proliferator-Activated Receptor α Mediates the Adaptive response to Fasting," <i>The Journal of Clinical Investigation</i> 103(11):1489-1498.		
	9.	Kersten, S. (2001). "Mechanisms of Nutritional and Hormonal Regulation of Lipogenesis," <i>EMBO Reports</i> 2(4):282-286.		
	10.	Loftus, T.M. et al. (June 30, 2000). "Reduced Food Intake and Body Weight in Mice Treated With Fatty Acid Synthase Inhibitors," <i>Science</i> 288:2379-2381.		
	11.	Ruiz, J.I. et al. (1997). "Quantification in the Subnanomolar Range of Phospholipids and Neutral Lipids by Monodimensional Thin-Layer Chromatography and Image Analysis," <i>Journal of Lipid Research</i> 38:1482-1489.		
	12.	Semenkovich, C.F. (1997). "Regulation of Fatty Acid Synthase (FAS)," <i>Prog. Lipid Res.</i> 36(10):43-53.		
	13.	Siguel, E.N. et al. (October 1987). "Criteria for Essential Fatty Acid Deficiency in Plasma as Assessed by Capillary Column Gas-Liquid Chromatography," <i>Clin. Chem.</i> 33(10):1869-1873.		
	14.	Soukas, A. et al. (2000). "Leptin-Specific Patterns of Gene Expression in White Adipose Tissue," <i>Genes & Dev.</i> 14:963-980.		
	15.	Tretheway, R.N. (April 2001). "Gene Discovery via Metabolic Profiling," <i>Curr. Opin. Biotechnol.</i> 12(2):135-138.		
	16.	Watkins, S.M. et al. (2002). "Lipid Metabolome-Wide Effects of the PPAR γ Agonist Rosiglitazone," <i>J. Lipid Res.</i> 43:1809-1817.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa-1109449



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/808,880
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	2	of	2	Attorney Docket Number	475512000400

	17.	Yin, D. et al. (1998). "Somatotropin-Dependent Decrease in Fatty Acid Synthase mRNA Abundance in 3T3-F442A Adipocytes is the Result of a Decrease in Both Gene Transcription and mRNA Stability," <i>Biochem. J.</i> 331:815-820.	
--	-----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-1109449